NCT01949948View on ClinicalTrials.gov

Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke

PHASE3CompletedINTERVENTIONAL
Enrollment

1,050

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Ischemic Stroke
Interventions
DRUG

Tenecteplase

0.4 mg/kg single bolus intravenously

DRUG

Alteplase

0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously

Trial Locations (13)

1309

Baerum Hospital, Rud

1474

Akershus University Hospital, Nordbyhagen

3004

Drammen Hospital, Drammen

3100

Tønsberg Hospital, Tønsberg

3710

Telemark Hospital, Skien

4017

Stavanger University Hosital, Stavanger

5021

Haukeland University Hospital, Bergen

5516

Haugesund Hospital, Haugesund

6400

Molde Hospital, Molde

6800

Førde Central Hospital, Førde

7006

St. Olav Hospital NTNU, Trondheim

8092

Nordland Hospital, Bodø

0424

Ullevål University Hospital, Oslo

All Listed Sponsors
collaborator

The Research Council of Norway

OTHER

lead

Lars Thomassen

OTHER

NCT01949948 - Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter